Key Points
- Collegium director Rita Balice-Gordon sold 3,650 shares on December 5 at an average price of $47.03 for proceeds of $171,659.50, reducing her stake by 6.49% to 52,629 shares (valued at about $2.48M); the sale was disclosed in an SEC filing.
- The stock opened at $47.03 with a one-year range of $23.23–$49.09, a market cap of roughly $1.49B, a P/E of 29.2, and recent quarterly results showing $1.26 EPS on $135.6M revenue.
- Analysts have trended positive recently—several upgrades and higher price targets (consensus "Buy" with a $47 target), including coverage from Barclays ($58 target) and upgrades from Weiss, Wall Street Zen and Zacks.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) Director Rita Balice-Gordon sold 3,650 shares of the firm's stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. The trade was a 6.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Collegium Pharmaceutical Stock Down 1.8%
NASDAQ:COLL opened at $47.03 on Wednesday. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $49.09. The stock has a 50-day moving average price of $39.86 and a two-hundred day moving average price of $35.61. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of 29.21 and a beta of 0.61. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The company had revenue of $135.55 million for the quarter. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.
Hedge Funds Weigh In On Collegium Pharmaceutical
A number of large investors have recently modified their holdings of COLL. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Collegium Pharmaceutical in the 1st quarter valued at about $3,085,000. Nuveen LLC acquired a new position in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $2,674,000. Public Sector Pension Investment Board raised its stake in shares of Collegium Pharmaceutical by 26.7% during the 1st quarter. Public Sector Pension Investment Board now owns 102,246 shares of the specialty pharmaceutical company's stock worth $3,052,000 after purchasing an additional 21,562 shares in the last quarter. Knott David M Jr boosted its holdings in shares of Collegium Pharmaceutical by 16.8% in the 1st quarter. Knott David M Jr now owns 38,473 shares of the specialty pharmaceutical company's stock valued at $1,148,000 after buying an additional 5,546 shares during the last quarter. Finally, Tejara Capital Ltd boosted its holdings in shares of Collegium Pharmaceutical by 288.4% in the 1st quarter. Tejara Capital Ltd now owns 111,792 shares of the specialty pharmaceutical company's stock valued at $3,337,000 after buying an additional 83,011 shares during the last quarter.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Weiss Ratings raised shares of Collegium Pharmaceutical from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday. HC Wainwright boosted their price objective on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the company a "buy" rating in a research report on Friday, November 7th. Wall Street Zen upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. Barclays assumed coverage on Collegium Pharmaceutical in a report on Monday. They issued an "overweight" rating and a $58.00 price target on the stock. Finally, Zacks Research raised Collegium Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $47.00.
View Our Latest Research Report on Collegium Pharmaceutical
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
